Therapeutic Vaccines: More Trials and Tribulations

Introduction

Therapeutic vaccines have faced numerous setbacks in recent years. The only three vaccines to reach the market have had insignificant sales, while the pipeline has seen numerous high-profile failures and no new product launches in three years. However, new 'off-the-shelf' generalized vaccines driven by genomic advances promise to remedy the commercial drawbacks of early personalized vaccines

Scope

In-depth coverage of over 200 marketed and pipeline therapeutic vaccines, including forecasts for sales up to 2010 and analysis of future trends

Profiles of 16 leading therapeutic vaccines companies, their strategic position, pipelines, partnerships and financial outlook

Discussion of the many challenges facing therapeutic vaccine developers, and how technology evolution is driving the industry forward

Analysis of big pharma's level of interest in the sector, their partnerships and pipelines

Highlights

Polyvalent, patient-specific vaccines have major commercial disadvantages that have limited their uptake. However, rapid scientific progress means that antigen-specific, generalized vaccines could soon offer comparable efficacy, to complement their strong commercial profile. As a result generalized vaccines are starting to dominate the pipeline.

Therapeutic vaccines development is seeing an increasing trend towards the use of multiple antigens (and adjuvants), to attack cancers or HIV from multiple angles. Combinations of therapies, and novel approaches such as prime-boost regimens are expected to yield exciting results. Partnerships will therefore become much more important

Therapeutic vaccine development is currently heavily weighted towards cancer vaccines, which account for 60.6% of all pipeline projects. However, the early-stage pipeline is starting to show greater interest in other therapeutic areas, from HIV and infectious disease to nicotine addiction, CNS and cardiovascular diseases

Reasons to Purchase

Understand the scientific and commercial issues that are impeding therapeutic vaccines, and learn how they can become a success in the future

Assess the entire pipeline of therapeutic vaccines with an interactive Excel model containing details of over 200 therapeutic vaccines in development

Analyze and benchmark leading companies' strategies and pipelines, as well as big pharma's interest in the sector

December 2005

PDF

Pages: 202
Table of Contents
Price: $7,600.00 / GBP3,800.00